Health committee  There are a few things. I do think it's really important that we appreciate how incomplete and tenuous the U.K. data is on AstraZeneca safety. Their MHRA, which reports on their Yellow Card system for vaccine safety, reported again last night our time, or early this morning, and

Health committee  I think the simple answer to that, without going into too many details, is an intolerance of allowing cases to rise in any manner. As I kind of alluded to, if we're titrating our response to health care system capacity, what we're doing is allowing Canadians unnecessarily to beco

Health committee  I've always felt that we need to, first and foremost, consider this pandemic to be a global pandemic, so we need to appreciate that Canadians won't be fully safe until everyone around the world is going to be safe. If we think of Canada and its borders, and everything within its

Health committee  Sorry, it's was for me. Thanks for the question. I was on mute. I think I'll address the first question later on, if we have time, but to the second question about monoclonal antibodies, I'll say a few things in response. I sit on and chair Ontario's scientific advisory table.

Health committee  Yes, I think I would absolutely consider it. I think there is emerging evidence that it is of some benefit. There are some challenges with it, especially the practicalities, but definitely, as time has gone on, if you can get patients onto combination monoclonal antibodies early

Health committee  Thanks so much. I have never paid attention when given any yellow card before, so I don't know why I should start now. Mr. Chair and honourable committee members, thanks for allowing me to address you. Before I start, I want to acknowledge that I'm currently speaking on what I b

Health committee  I think there are a few options available. Some of those would require legislation. The Public Health Agency of Canada was born out of the SARS Commission and a recognition that we did need a strong federal response to infectious diseases and pandemics. Over time, PHAC has seen i

Health committee  Although I have a personal view on it, I think that Dr. Langley has more expertise than I do to answer that.

Health committee  I do, as a matter of fact.

Health committee  That's probably a 10-hour conversation. I will try to narrow it as much as possible and focus first on the public health measures you have suggested. I think one thing we haven't done well in Canada in particular is to take on a national or pan-Canadian strategy. Instead, we ha

Health committee  There is really not much more to add to what Dr. Langley said. The real challenge is that most of our research experience is in adults younger than age 65, but the growing real-world experience is that it is effective, but it's going to be a matter of time in the post-marketing d

Health committee  I'm not exactly sure what the question is, but I can comment on it. I will say that the data that we have from the trials so far is markedly limited. The number of end points is quite small. There are two real challenges with bamlanivimab. One is identifying the people who will

Health committee  Thank you, Mr. Chair, and honourable committee members. It's an honour to be able to address this committee. Before I begin, I'd like to acknowledge that I'm currently speaking from what I believe to be the unceded ancestral territory of the Haudenosaunee, which is where my fami